Opioid prescribing among new users for non-cancer pain in the USA, Canada, UK, and Taiwan: A population-based cohort study

Autor: Therese Sheppard, Usman Iqbal, Robyn Tamblyn, Jack Shiansong Li, David L. Buckeridge, Meghna Jani, Shelly A. Vik, David W. Bates, Colin Weaver, Nadyne Girard, William G Dixon, Judy E. Seidel

Publikováno v: PLoS Medicine, Vol 18, Iss 11 (2021)
Jani, M, Girard, N, Bates, D, Buckeridge, D, Sheppard, T, Li, J S, Iqbal, U, Vik, S, Weaver, C, Seidel, J, Dixon, W & Tamblyn, R 2021, ' Opioid prescribing among new users for non-cancer pain in USA, Canada, UK and Taiwan : a population-based cohort study ', PL o S Medicine, vol. 18, no. 11, e1003829, pp. 1-15 . https://doi.org/10.1371/journal.pmed.1003829
PLoS Medicine
PLoS Medicine, Vol 18, Iss 11, p e1003829 (2021)

Background The opioid epidemic in North America has been driven by an increase in the use and potency of prescription opioids, with ensuing excessive opioid-related deaths. Internationally, there are lower rates of opioid-related mortality, possibly

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c084d7e0deea9b78148596fb92cf1a5
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601614/?tool=EBI

388 Preliminary results from KEYNOTE-A36, a study of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab or chemotherapy in specified advanced solid tumors

Autor: Laura L. Carter, Jack Shiansong Li, Beatrice Ferguson, Wells A. Messersmith, Wungki Park, Johanna C. Bendell, Jean-Marie Bruey, Lei Zhou, Jakob Dupont, Marya F. Chaney, Drew W. Rasco, Johann S. de Bono, Andrea Wang-Gillam

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)

Background GB1275 is a first-in-class CD11b modulator that reduced myeloid-derived suppressor cells (MDSCs) and tumor associated macrophages (TAMs), repolarized M2 immunosuppressive TAMs to an M1 phenotype, and increased tumor infiltration of activat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92fdb71e1a3be033e75f319cdbe78965
https://doaj.org/article/b5c92c8be7a5471d9ef4afa2e54ec366

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial

Autor: Josep Tabernero, Jack Shiansong Li, Kamel Djazouli, Werner Scheithauer, Volker Kunzmann, Stefano Ferrara, Michele Reni

Publikováno v: OncoTargets and Therapy. 10:591-596

PURPOSE The global Phase III MPACT trial demonstrated superior efficacy of nab-paclitaxel plus gemcitabine over gemcitabine alone as first-line treatment for metastatic pancreatic cancer. Region was a randomization stratification factor in the MPACT

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6e7aabd197a5200ace8716c999bff2d4
https://doi.org/10.2147/ott.s124097

Preliminary clinical and biologic results of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab, in advanced solid tumors (KEYNOTE A36)

Autor: Johanna C. Bendell, Jack Shiansong Li, Wungki Park, John H. Strickler, Haeseong Park, Kartik Raghupathi, Wells A. Messersmith, Laura L. Carter, Jean-Marie Bruey, Drew W. Rasco, Jakob Dupont, Marya F. Chaney, Johann S. de Bono, Lei Zhou

Publikováno v: Journal of Clinical Oncology. 39:2505-2505

2505 Background: GB1275 is a first-in-class, oral CD11b modulator that reduced myeloid-derived suppressor cells (MDSCs) and tumor associated macrophages (TAMs), repolarized M2 immunosuppressive TAMs to an M1 phenotype, resulting in increased tumor in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a91bdba1ba15444442855772db65feb4
https://doi.org/10.1200/jco.2021.39.15_suppl.2505

A phase I/II study of GB1275, a first-in-class oral CD11b modulator, alone, and combined with pembrolizumab in specified advanced solid tumors or with chemotherapy in metastatic pancreatic cancer (KEYNOTE-A36)

Autor: Jakob Dupont, Wungki Park, Johanna C. Bendell, Laura L. Carter, Lei Zhou, Eileen M. O'Reilly, Anna Galkin, Jack Shiansong Li, Drew W. Rasco, Beatrice Ferguson, Andrea Wang-Gillam, Wells A. Messersmith, David Nickle, Marya F. Chaney

Publikováno v: Journal of Clinical Oncology. 38:3085-3085

3085 Background: GB1275 is a first-in-class CD11b modulator that reduced myeloid-derived suppressor cells (MDSCs) and tumor associated macrophages (TAMs) at the tumor site, repolarized M2 immunosuppressive TAMs to an M1 phenotype, and increased tumor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::be338611a24d40984a52cf76a3630e1e
https://doi.org/10.1200/jco.2020.38.15_suppl.3085